Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 15/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 15/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 15/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 15/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 15/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 15/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259795 | 0.94 | CSNK2A2 (0.57) | CSNK2A2CSNK2A1PSEN1PSEN2APH1B | |
| SCHEMBL1260970 | 0.91 | PSEN1 (0.54) | CSNK2A2CSNK2A1PSEN1PSEN2APH1B | |
| SCHEMBL1259759 | 0.91 | CSNK2A2 (0.49) | CSNK2A2CSNK2A1PSEN1PSEN2APH1B | |
| SCHEMBL1258771 | 0.90 | PSEN1 (0.51) | CSNK2A2CSNK2A1PSEN1PSEN2APH1B | |
| SCHEMBL1259990 | 0.86 | PSEN1 (0.48) | CSNK2A2CSNK2A1PSEN1PSEN2APH1B | |
| SCHEMBL1259733 | 0.86 | PSEN1 (0.49) | CSNK2A2CSNK2A1PSEN1PSEN2APH1B | |
| SCHEMBL1259751 | 0.85 | CSNK2A2 (0.56) | CSNK2A2CSNK2A1PSEN1PSEN2APH1B | |
| SCHEMBL1259842 | 0.85 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1258863 | 0.83 | PSEN1 (0.47) | CSNK2A2CSNK2A1PSEN1PSEN2APH1B | |
| SCHEMBL1258812 | 0.83 | PSEN1 (0.47) | CSNK2A2CSNK2A1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879889-B2 | administering (2S)-2-{[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino}-N-{5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl}pentanamide, for the treatment of Alzheimer's disease | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-7563903-B2 | Acylaminothiazole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2009-07-21 | — | — | US | disclosed |
| EP-1590337-B1 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME AS BETA-AMYLOID PEPTIDE PRODUCTION INHIBITORS | SANOFI AVENTIS (FR) | 2008-08-13 | — | — | EP | disclosed |
| US-20060052426-A1 | Acylaminothiazole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | ACAT1, GLS2, GLS | CSNK2A2 845/4885CSNK2A1 824/4885PSEN1 2815/4885 |
| US-20060052426-A1 | Acylaminothiazole derivatives, their preparation and their therapeutic use | CBR3, CBR1, NAT1 | CSNK2A2 1633/4885CSNK2A1 1345/4885PSEN1 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.